Study Groups

WWARN facilitates a number of collaborative Study Groups to undertake individual patient data meta-analyses to answer specific research questions about malaria treatments and antimalarial drug resistance. Gathering and combining data sets from multiple studies increases sample sizes, so that effects, including smaller effects, and effects on sub-populations can be identified with greater certainty. Working together and combining data from different regions and populations is improving our understanding of drug resistance and strengthening global efforts to control and eventually eliminate malaria.

clinic_in_bamako
i
Dominic Chavez World Bank

Lumefantrine – ARV PK/PD Study Group

An analysis of pooled individual patient data to determine the effect of antiretroviral (ARV) drug-drug interactions and HIV disease on lumefantr...

An analysis of pooled individual patient data to determine the effect of antiretroviral (ARV) drug-drug interactions and HIV disease on lumefantrine pharmacokinetics (and pharmacodynamics).

This study group has just opened for data collection. If you have any data you would like to share, or if you would like to participate in the project, please contact pharmacology@wwarn.org.

show more

Paediatric single low-dose primaquine safety study group

The paediatric single low-dose (SLD) primaquine safety study group aims to describe and compare the safety of SLD primaquine for transmission blocking...

The paediatric single low-dose (SLD) primaquine safety study group aims to describe and compare the safety of SLD primaquine for transmission blocking of Plasmodium falciparum in young children (under 5 years of age) with that in older children and adults.

show more

Alternative drugs and strategies to prevent malaria in pregnancy Study Group

The Alternative MiP Prevention Strategies (AMPS) Study Group’s aim is to determine the safety and efficacy of novel strategies for the control of mala...

The Alternative MiP Prevention Strategies (AMPS) Study Group’s aim is to determine the safety and efficacy of novel strategies for the control of malaria in pregnancy including intermittent preventive therapy (IPTp) with dihydroartemisinin-piperaquine (DP) and intermittent screening and treatment (ISTp) with DP or artemether-lumefantrine (AL).

show more
Pregnant woman sitting against a wall

Alternative Strategies to Prevent Malaria in Pregnancy Study Group

The Alternative MiP Prevention Strategies (AMPS) Study Group’s aim is to determine the safety and efficacy of novel strategies for the control of mala...

The Alternative MiP Prevention Strategies (AMPS) Study Group’s aim is to determine the safety and efficacy of novel strategies for the control of malaria in pregnancy, specifically intermittent screening and treatment (ISTp), with an artemisinin-based combination therapy (ACT).

show more

Dihydroartemisinin-Piperaquine for Intermittent Preventive Treatment in Pregnancy (IPTp-DP) Study Group

The Dihydroartemisinin-Piperaquine for Intermittent Preventive Treatment in Pregnancy Study Group aims to determine the safety and efficacy of intermi...

The Dihydroartemisinin-Piperaquine for Intermittent Preventive Treatment in Pregnancy Study Group aims to determine the safety and efficacy of intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine (DP) compared to IPTp with sulfadoxine-pyrimethamine (SP), for the prevention of malaria and adverse birth outcomes among pregnant women in sub-Saharan Africa.

show more

Piperaquine Pharmacokinetics in Pregnancy Study Group

Determining the effects of pregnancy on piperaquine pharmacokinetics. The analysis aims to contribute evidence needed to inform recommendations on the...

Determining the effects of pregnancy on piperaquine pharmacokinetics. The analysis aims to contribute evidence needed to inform recommendations on the use and optimal dosing of piperaquine in pregnant women.

Determining the effects of pregnancy on piperaquine pharmacokinetics. The analysis aims to contribute evidence needed to inform recommendations on the use and optimal dosing of piperaquine in pregnant women.

 

show more

SP Resistance Data Access Group

The sulphadoxine-pyrimethamine (SP) resistance Data Access Group’s aim is to provide maps and open access to the most recent data on molecular markers...

The sulphadoxine-pyrimethamine (SP) resistance Data Access Group’s aim is to provide maps and open access to the most recent data on molecular markers of SP resistance to help policy makers make informed decisions with regard to use of SP for intermittent preventive treatment of malaria in pregnancy (IPTp) or seasonal malaria chemoprevention (SMC).

show more

Vivax After Falciparum Study Group

This Study Group will explore the link between P. vivax recurrence and prior P. falciparum treatment, including increased risk of vivax para...

This Study Group will explore the link between P. vivax recurrence and prior P. falciparum treatment, including increased risk of vivax parasitaemia due to acute malaria infection.

show more

ACT-ARV Haematology Study Group

This is an extension of the WWARN Haemoglobin-Haematocrit Relationship in Malaria Study Group and the Antimalarial–Antiretroviral Analy...

This is an extension of the WWARN Haemoglobin-Haematocrit Relationship in Malaria Study Group and the Antimalarial–Antiretroviral Analyses Study Group. These groups aimed to consider the effect of HIV disease and co-administration of widely-used antiretroviral drugs (ARVs) on artemisinin-based combination therapies (ACTs).  

show more

AS-MQ Dose Impact Study Group

A pooled analysis assessing the effect of mg/kg dosing strategies on the risk of treatment failure in patients treated with the currently recommended ...

A pooled analysis assessing the effect of mg/kg dosing strategies on the risk of treatment failure in patients treated with the currently recommended dose of artesunate-mefloquine (AS-MQ).

Research groups with relevant data have been contacted with data collection and curation still ongoing. Analysis will start in late 2016 and drafting publication in expected in 2018.

show more

Artemether-Lumefantrine / ARV PK Study Group

A meta-analysis of individual patient data (IPD) to determine the effect of antiretroviral (ARV) drug-drug interactions and HIV disease on artemether ...

A meta-analysis of individual patient data (IPD) to determine the effect of antiretroviral (ARV) drug-drug interactions and HIV disease on artemether and lumefantrine pharmacokinetics (PK). The analysis aims to contribute evidence needed to inform recommendations on the use and optimal dosing of artemether-lumefantrine (AL) in HIV-infected patients.

show more
lymphocyte with rbcs

White Blood Cell Count in Malaria Study Group

Determining what affects White Blood Cell (WBC) count at baseline and during acute phase of malaria infection.  
mothers and babies

Paediatric single low-dose primaquine efficacy study group

The paediatric single low-dose (SLD) primaquine efficacy study group aims to assess and compare the efficacy of SLD primaquine for transmission blocki...

The paediatric single low-dose (SLD) primaquine efficacy study group aims to assess and compare the efficacy of SLD primaquine for transmission blocking of Plasmodium falciparum in young children (under 5 years of age) with that in older children and adults

show more

Molecular Markers of Resistance in West Africa Study Group

This Study Group aims to bring together and explore the latest evidence on the prevalence of molecular markers associated with antimalarial drug resis...

This Study Group aims to bring together and explore the latest evidence on the prevalence of molecular markers associated with antimalarial drug resistance in West African Countries.

show more

Vivax and Ovale Paediatric Primaquine Gastrointestinal Tolerability Study Group

Analysis of how age impacts the effect of primaquine dose on gastrointestinal tolerability in patients with Plasmodium vivax and Plasmodium ovale mala...

Analysis of how age impacts the effect of primaquine dose on gastrointestinal tolerability in patients with Plasmodium vivax and Plasmodium ovale malaria

show more

Vivax and Ovale Paediatric Primaquine Haematological Safety Study Group

Analysis of how age impacts the effect of primaquine dose on haematological safety in patients with Plasmodium vivax and Plasmodium ovale malaria

Intermittent preventive treatment in pregnancy (IPTp) and SP-resistance-associated mutations Study Group

The overall aim of the IPTp and SP-resistance-associated mutations Study Group is to quantify how parasites with the sextuple mutant pfdhps and pfdhfr...

The overall aim of the IPTp and SP-resistance-associated mutations Study Group is to quantify how parasites with the sextuple mutant pfdhps and pfdhfr haplotype* modify the effect of IPTp on maternal and infant outcomes.

show more

ACT-ARV Safety Study Group

This is an extension of a planned dihydroartemisinin-piperaquine (DP) Safety Study Group, which aims to consider the effect of HIV disease and co-admi...

This is an extension of a planned dihydroartemisinin-piperaquine (DP) Safety Study Group, which aims to consider the effect of HIV disease and co-administration of widely-used antiretroviral (ARVs) on the safety of DP. Due to a lack of available DP studies, the individual patient data (IPD) meta-analysis will have greater public health value when these results were compared to other ACTs.

show more

SP Resistance Study Group

The Sulphadoxine-Pyrimethamine (SP) resistance Study Group’s aim is to provide open access to, and establish maps with, the most recent data on SP res...

The Sulphadoxine-Pyrimethamine (SP) resistance Study Group’s aim is to provide open access to, and establish maps with, the most recent data on SP resistance to inform policy decisions on the clinical effectiveness of SP when provided as part of intermittent preventive treatment of malaria in pregnancy (IPTp) or seasonal malaria chemoprevention (SMC).

show more

ACT Asia Baseline Study Group

Baseline information on parasitological response to ACTs in AsiaA pooled analysis to assess the baseline early parasitological response after artemisi...

Baseline information on parasitological response to ACTs in Asia

A pooled analysis to assess the baseline early parasitological response after artemisinin combination therapy (ACT) treatment in Asia. The analysis compiles the day 3 parasite positivity rates (PPR) in patients with uncomplicated Plasmodium falciparum malaria enrolled in ACT clinical efficacy trials conducted in Asia.

Data gathering and curation has started. Data meeting the inclusion criteria has already been collected and standardised from over 12,000 patients. Data analysis will start April 2015 with a manuscript schedules for submission and publication by December 2015. 

show more